Fredun Pharma Q1 FY27 Revenue Jumps 90% to ₹228.25 Cr
Fredun Pharmaceuticals Limited announced its unaudited financial results for Q1 FY27, showcasing a significant year-on-year growth. Total income surged by 90.44% to ₹228.25 Cr from ₹119.86 Cr in Q1 FY26. EBITDA increased by 92.90% to ₹32.78 Cr, with EBITDA margin slightly improving by 18 basis points to 14.36%. Net profit saw a substantial rise of 94.63% to ₹13.17 Cr, and Net Profit margin improved by 12 basis points to 5.77%. Basic EPS grew by 66.71% to ₹23.89. The company also highlighted a bonus share allotment of 1.10 crore shares in a 2:1 ratio on July 17, 2026. Management expressed optimism about future growth driven by investments in branded portfolios, new categories, and manufacturing capabilities.
Key Highlights
- Revenue grew 90.44% YoY to ₹228.25 Cr in Q1 FY27.
- EBITDA surged 92.90% YoY to ₹32.78 Cr.
- Net Profit jumped 94.63% YoY to ₹13.17 Cr.
- Basic EPS increased by 66.71% YoY to ₹23.89.
- Company allotted 1.10 crore bonus equity shares in a 2:1 ratio.
Price Impact
More from FREDUN
More in Quarterly Result